Evidence map›Paper›PMID 20504925›Full record

ArticleJournal of virology2010

In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Kurt I Kamrud, V McNeil Coffield, Gary Owens, Christin Goodman, Kim Alterson, Max Custer, Michael A Murphy, Whitney Lewis, Sarah Timberlake, Elizabeth K Wansley and 2 more

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Swine influenza A virus: challenges and novel vaccine strategies.Frontiers in cellular and infection microbiology · 2024
    Review
  3. Viral Replicon Systems and Their Biosafety Aspects.Applied biosafety : journal of the American Biological Safety Association · 2023
    Review
  4. Article
  5. Self-Replicating RNA Viruses for RNA Therapeutics.Molecules (Basel, Switzerland) · 2018
    Review
  6. Review
  7. Review
  8. MicroRNA-regulated viral vectors for gene therapy.World journal of experimental medicine · 2016
    Review
  9. RNA-based drugs and vaccines.Expert review of vaccines · 2015
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kurt I KamrudAlphaVax, Inc., Research Triangle Park, North Carolina 27709, USA. Kamrud@alphavax.com
V McNeil Coffield
Gary Owens
Christin Goodman
Kim Alterson
Max Custer
Michael A Murphy
Whitney Lewis
Sarah Timberlake
Elizabeth K Wansley
Peter Berglund
Jonathan Smith
Triangle · USAlphaVax (United States) · US

Funding

Alphavirus Replicon Vaccines to Encephalitis VirusesU01AI056438 · NIAID · ALPHAVAX HUMAN VACCINES, INC. · PI SMITH, JONATHAN FOWLER · 2003 to 2007
$7.5M
Development of an VEE Replicon Vaccine Against SmallpoxUC1AI067183 · NIAID · ALPHAVAX HUMAN VACCINES, INC. · PI KAMRUD, KURT I · 2005 to 2005
$3.3M
Dose Optimization, Production & Tox Testing of Replicon-Vaccines for SmallpoxU01AI078010 · NIAID · ALPHAVAX HUMAN VACCINES, INC. · PI OLMSTED, ROBERT A · 2008 to 2009
$1.0M
NIAID NIH HHS 1 UC1 AI067183-01NIAID NIH HHS 5 U01 AI056438-03NIAID NIH HHS U01 AI056438NIAID NIH HHS U01 AI078010NIAID NIH HHS UC1 AI067183
6 · The paper itself

Abstract

Alphavirus-based replicon vector systems (family Togaviridae) have been developed as expression vectors with demonstrated potential in vaccine development against both infectious diseases and cancer. The single-cycle nature of virus-like replicon particles (VRP), generated by supplying the structural proteins from separate replicable helper RNAs, is an attractive safety component of these systems. MicroRNAs (miRNAs) have emerged as important cellular RNA regulation elements. Recently, miRNAs have been employed as a mechanism to attenuate or restrict cellular tropism of replication-competent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and picornaviruses as well as nonreplicating lentiviral and adenoviral vectors. Here, we describe the incorporation of miRNA-specific target sequences into replicable alphavirus helper RNAs that are used in trans to provide the structural proteins required for VRP production. VRP were found to be efficiently produced using miRNA-targeted helper RNAs if miRNA-specific inhibitors were introduced into cells during VRP production. In the absence of such inhibitors, cellular miRNAs were capable of downregulating helper RNA replication in vitro. When miRNA targets were incorporated into a replicon RNA, cellular miRNAs were capable of downregulating replicon RNA replication upon delivery of VRP into animals, demonstrating activity in vivo. These data provide the first example of miRNA-specific repression of alphavirus replicon and helper RNA replication and demonstrate the feasibility of miRNA targeting of expression vector helper functions that are provided in trans.

Indexed as

Gene TargetingGenetic VectorsAlphavirusAnimalsChlorocebus aethiopsFemaleMiceMice, Inbred BALB CMicroRNAsRNA, ViralVero CellsMicroRNAsRNA, Viral

Identifiers

PMID20504925
PMCPMC2897628
OpenAlexW2152865046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.